Loading clinical trials...
Loading clinical trials...
A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.
Conditions
Interventions
DPX-Survivac
Cyclophosphamide
+1 more
Locations
23
United States
The University of Arizona Cancer Center
Tucson, Arizona, United States
Cedars Sinai Medical Center: Samuel Oschin Comprehensive Cancer Center
Los Angeles, California, United States
Boca Raton Regional Hospital, Lynn Cancer Institute
Boca Raton, Florida, United States
Hematology Oncology Associates of the Treasure Coast
Port Saint Lucie, Florida, United States
Comprehensive Hematology and Oncology
St. Petersburg, Florida, United States
Winship Cancer Institute: The Emory Clinic
Atlanta, Georgia, United States
Start Date
December 21, 2018
Primary Completion Date
December 31, 2023
Completion Date
December 31, 2023
Last Updated
March 31, 2022
NCT07175441
NCT06043817
NCT03050268
NCT06257264
NCT06964009
NCT07144280
Lead Sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions